Usha Bughani

Title: Usha Bughani – Pioneering Innovator in Immunotherapy

Introduction

Usha Bughani is a prominent inventor based in Bengaluru, India, known for her significant contributions to the field of immunotherapy. With a strong focus on cancer treatment, she has been granted three patents that showcase her innovative approaches to combating disease through advanced therapeutic methods.

Latest Patents

One of Usha Bughani's latest patents involves immunotherapy methods utilizing anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins. This invention offers a groundbreaking composition and method aimed at treating subjects afflicted with cancer. The composition comprises therapeutically effective amounts of an anti-Programmed Death-Ligand 1 (PD-L1) antibody along with a targeted immunomodulatory fusion protein, which includes both a tumor targeting moiety and an immunomodulatory moiety. This innovative approach is designed to counteract the immune tolerance often exhibited by cancer cells.

Another significant patent focuses on the use of a CD6 binding partner and related methods. This disclosure outlines novel methods for the treatment and prevention of conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes. Specifically, it incorporates the use of an anti-CD6 antibody to address autoimmune responses driven by reactive Th17 and Th1 lymphocytes. The methods provided have additional applicability in modulating immune responses and reducing inflammation mediated by Th17 cells by suppressing the production of the cytokine IL-23R.

Career Highlights

Usha Bughani's career is marked by her tenure at Biocon Limited, a leading biopharmaceutical company. Her work exemplifies the intersection of science and innovation, with a commitment to developing transformative therapies for critical health challenges.

Collaborations

Throughout her journey, Usha has collaborated with fellow innovators and professionals such as Pradip Nair and Ramakrishnan Melarkode. These partnerships are instrumental in fostering a creative environment that promotes cutting-edge research and development in the field of biotechnology.

Conclusion

Usha Bughani stands out as a trailblazing inventor in immunotherapy, contributing to important advancements with her three patents. Her work at Biocon Limited, combined with her collaborative spirit, paves the way for future innovations aimed at treating cancer and enhancing immune responses. As she continues her work, Usha's contributions are sure to have a lasting impact on the medical field.